HHLA2 and neoplasm: In vitro experiments showed that HHLA2 promotes PTC cell progression, indicating its function as a tumor promoter, thereby suggesting that targeting HHLA2 could represent a novel therapeutic approach for PTC (Niu et al. 2022a).